Fespixon® is not approved by the U.S. FDA. This website is intended for international healthcare professionals outside the U.S. only.
Bonvadis® is a breakthrough topical cream clinically proven to accelerate healing across all wounds-including diabetic foot ulcers, venous and pressure ulcers, post-surgical wounds, and burns. Its unique and evidence-based formula delivers fast, safe, and effective results, even for the most challenging wounds.
Bonvadis® is a breakthrough topical cream clinically proven to accelerate healing across all wounds-including diabetic foot ulcers, venous and pressure ulcers, post-surgical wounds, and burns. Its unique and evidence-based formula delivers fast, safe, and effective results, even for the most challenging wounds.
Bonvadis® is indicated for a wide spectrum of wounds— including acute wounds, chronic wounds such as DFU, post-surgical wounds, and 1stand 2nd degree burns. Its clinical versatility is supported by multinational clinical trials and regulatory approvals across the US, Saudi Arabia, and other key markets.
Bonvadis® is indicated for a wide spectrum of wounds— including acute wounds, chronic wounds such as DFU, post-surgical wounds, and 1stand 2nd degree burns. Its clinical versatility is supported by multinational clinical trials and regulatory approvals across the US, Saudi Arabia, and other key markets.
Bonvadis® is backed by robust clinical evidence demonstrating significant improvements in complete healing rates and limb preservation. In both clinical and real-world studies, it delivers fast, effective results—even in high-risk patients.
Up to 80% complete healing observed in real-world studies, with many wounds closing within 2–6 weeks.
In a randomized controlled trial (RCT) for diabetic foot ulcers, Bonvadis® achieved a 60.7% healing rate, outperforming standard care (p=0.0001).
Significant reduction in amputation risk compared to the other advanced treatments.
Bonvadis® is backed by robust clinical evidence demonstrating significant improvements in complete healing rates and limb preservation. In both clinical and real-world studies, it delivers fast, effective results—even in high-risk patients.
Up to 80% complete healing observed in real-world studies, with many wounds closing within 2–6 weeks.
In a randomized controlled trial (RCT) for diabetic foot ulcers, Bonvadis® achieved a 60.7% healing rate, outperforming standard care (p=0.0001).
Significant reduction in amputation risk compared to the other advanced treatments.
Bonvadis® supports healing across the full wound care continuum by creating an optimal moist microenvironment. It helps resolve chronic inflammation, promote epithelialization and support tissue remodeling with minimal scarring. It is especially effective for chronic, infected, or non-healing wounds, including those in high-risk patients such as individuals on dialysis.
Bonvadis® supports healing across the full wound care continuum by creating an optimal moist microenvironment. It helps resolve chronic inflammation, promote epithelialization and support tissue remodeling with minimal scarring. It is especially effective for chronic, infected, or non-healing wounds, including those in high-risk patients such as individuals on dialysis.
Bonvadis® gentle, botanical-based formulation is naturally free from immune rejection, infection risk, and proteolytic degradation. Clinically proven for long-term and repeated use, Bonvadis® helps minimize scarring with no reported adverse effects.
Bonvadis® gentle, botanical-based formulation is naturally free from immune rejection, infection risk, and proteolytic degradation. Clinically proven for long-term and repeated use, Bonvadis® helps minimize scarring with no reported adverse effects.
Bonvadis® is designed for easy, effective wound care at home. It requires no refrigeration, applies easily, and empowers caregivers to manage treatment outside of clinical settings — reducing the need for frequent outpatient visits and helping lower overall healthcare costs. Most wounds require only 1–2.5 tubes for complete healing, making it a cost-efficient solution for long-term care.
Bonvadis® is designed for easy, effective wound care at home. It requires no refrigeration, applies easily, and empowers caregivers to manage treatment outside of clinical settings — reducing the need for frequent outpatient visits and helping lower overall healthcare costs. Most wounds require only 1–2.5 tubes for complete healing, making it a cost-efficient solution for long-term care.
Bonvadis® delivers superior cost-effectiveness compared to advanced therapies such as skin substitutes. It can be used as a standalone treatment or in combination with other modalities, including standard dressings, and negative pressure wound therapy (NPWT) , making it highly adaptable to diverse clinical settings and wound care protocols.
Bonvadis® delivers superior cost-effectiveness compared to advanced therapies such as skin substitutes. It can be used as a standalone treatment or in combination with other modalities, including standard dressings, and negative pressure wound therapy (NPWT) , making it highly adaptable to diverse clinical settings and wound care protocols.
We’ve utilized the product basically and all the way through the algorithm. The product has just been superior to everything that we’ve been doing up to this point.
-Dr. Brock A. Liden/DPM, FABWH, FAPWCA
Diabetic Foot Ulcer
A 100 cm2 Tendon-exposed DFU
Diabetic Foot Ulcer
A Wagner grade 4 Ulcer Saved from Amputation
Post-surgical Wound
2nd Degree Burn
Yes. Clinical cases have shown faster wound bed preparation and healing when Bonvadis® is used concurrently with NPWT. It’s also helpful before skin grafts.
The mechanism of Bonvadis® is to regulate the wound immune environment but Povidone-Iodine or Hydrogen Peroxide will interrupt the immune environment and hinder granulation.
